About us

InsuLine medical was founded in Israel by an experienced team, with specific experience in the medical device arena, and the diabetes care market.

InsuLine’s mission is to develop and market technologies to improve the clinical effectiveness of devices and drugs, for type I and type II diabetics. To date, the company has conducted a series of over 100 human clinical studies to demonstrate the safety and effectiveness of the first generation InsuPatch device.

The product has already received a CE mark for marketing in the EU and the company is now seeking FDA approval for it. InsuLine has filed several patents that protect the technology and related devices and methods.

InsuLine is backed by leading VC’s and a panel of world class medical advisors including: William V. Tamborlane MD, Professor & Chief of Pediatric Endocrinology and Diabetes at Yale University School of Medicine, New Haven, Connecticut. David C. KLONOFF MD, F.A.C.P, Clinical Professor of Medicine, U.C. San Francisco Editor-in-Chief, Journal of Diabetes Science and Technology , Medical Director, Mills-Peninsula Diabetes Research Institute, San Mateo, California Itamar Raz, MD, Head Diabetes Unit Hadassah Medical Center, Jerusalem Stuart Alan Weinzimer, M.D., Associate Professor of Pediatrics, Pediatric Endocrinology & Diabetes Yale University School of Medicine, New Haven, Connecticut